Richard S Levy

Director Richard S Levy sells 5,682 shares at $515.44 avg ($2.9M) at MDGL; 10b5-1 plan

Richard S Levy, a director at Madrigal Pharmaceuticals, executed 12 separate sales totaling 5,682 shares for $2,928,716.43 on 2026-05-22 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-20, reducing his holdings by -20.5% vs pre-transaction holdings. The company is unprofitable (full-year net income was negative) while showing explosive revenue growth of +432.0% year-over-year, creating valuation tension. Across his cross-ticker track record, Levy's prior 19 sells averaged +8.3% returns over 30 days post-execution, though his same-ticker history at MDGL (5 prior sells in November 2025) showed mixed 30-day outcomes (ranging 7.8%–10.8%) followed by consistent 90-day declines. The scheduled nature of this sale under 10b5-1 removes discretionary timing as a signal of conviction or concern.

Director Levy Richard S sold 8,500 shares across 14 transactions on 2025-11-13 for $4,428,197.57 ($4.4M)

Director Richard S. Levy executed 14 separate sales totaling 8,500 shares (8.5K shares) for $4,428,197.57 ($4.4M) on 2025-11-13 at prices ranging from $514.67 to $530.21, with a blended average price of $520.96. This represents a -28.6% reduction in his position, bringing holdings from 29,697 shares (29.7K shares) to 21,197 shares (21.2K shares). The stock is currently at $529.21, -2.3% from its 52-week high of $541.50, and has appreciated 22.1% over the past 30 days and 43.1% over the past 90 days. Notably, Levy's prior SAME-TICKER HISTORY at MDGL shows 4 of 5 prior sales executed in late October 2024 were poorly timed, with 90-day returns ranging from +11.2% to +12.7% (the stock rose after those sales), while his cross-ticker track record shows a 9.09% well-timed rate across 11 prior sells. The company posted $287,268,000.00 ($287.3M) in revenue but $-114,190,000.00 ($-114.2M) in net income in its most recent quarter, with annual profitability also negative.

Director Levy buys 20,000 TARA shares at $3.19; stock down -52.2% from 52-week high.

Director Richard S Levy purchased 20,000 shares at $3.19, increasing his holdings by 64.5% from 31,000 to 51,000 shares in a company that is unprofitable with -$11.9M net income and only $2.9M quarterly revenue. The stock has declined -52.2% from its 52-week high of $6.67 and is down -20.2% over the past 30 days. Across all of Levy's open-market transactions, his prior 11 sells achieved a 90d well-timed rate of 9.09%, indicating generally poor timing on exits. This buy occurs against a backdrop of material weakness in both the stock price and company fundamentals, with the director substantially expanding his position despite recent downward momentum.

Director Levy sold 5,000 MDGL shares at $350.00 on 2024-11-07; stock up +66.3% in 30 days, down -31.2% from prior holdings.

Levy Richard S sold 5,000 shares ($1.8M) on 2024-11-07, reducing his stake from 16,012 to 11,012 shares. The timing coincides with a sharp rally: MDGL is up +66.3% over the 30 days prior to the sale and sits at $350.70, within 1.2% of its 52-week high of $354.85. Notably, Levy executed four additional sales on 2024-11-01 (outcomes not yet measurable), suggesting a structured reduction of his position during this volatility. His cross-ticker track record shows a poor 0.00% well-timed rate on sells (averaging +7.6% returns 90 days after selling), and his only prior MDGL sale on 2024-04-01 also missed a gain, posting a +5.6% 90-day return. Against the backdrop of the company's substantial losses ($-107.0M net income on $62.2M revenue in the latest quarter), the concentrated selling during an elevated price period may signal caution on valuation following the recent run-up.

Director Levy Richard S sold 5,000 shares of MDGL for $1,504,703.41 on 2024-11-01 at blended average $300.94, reducing stake by 31.2%.

Richard S Levy, a director at Madrigal Pharmaceuticals, executed 4 separate sales totaling 5,000 shares for $1,504,703.41 on 2024-11-01, reducing his position from 16,012 to 11,012 shares—a 31.2% reduction. The sales occurred at prices ranging from $300.10 to $304.29, with the stock currently trading at $337.61 (37.2% above the blended average transaction price of $300.94), placing this sale near the 52-week low point of the recent rally; the stock has gained 62.0% over the past 30 days and 44.2% over 90 days. Notably, across Levy's 5 prior sales at MDGL—all executed on 2024-04-01—the stock rose 5.6% to 9.5% over the subsequent 90 days, with 0 of 5 prior sales proving well-timed (the company remained unprofitable, posting a $-107.0M net loss on $62.2M in quarterly revenue). This sale, executed as the stock approaches all-time highs after a sharp rally, departs from a pattern where Levy's prior dispositions were consistently followed by upward moves.